|First Author, Year (Ref. #)||Experimental AMI Model||Cardioprotective Agents or Interventions||Cardioprotective Effect||Cardiomyocyte and Noncardiomyocyte Targets|
|Koshinuma et al., 2014 (42)||Isolated guinea pig heart||Z-VAD during ischemia and first 30 min of reperfusion|
Necrostatin-1 during ischemia and first 30 min of reperfusion
|Additive effects on reducing MI size||Z-VAD—apoptosis inhibition|
|Yang et al., 2015 (60)||In vivo rat||Cangrelor at reperfusion|
Endonuclease III at reperfusion
|Additive effects of cangrelor and endonuclease III on reducing MI size||Cangrelor, P2Y12 inhibitor—platelets|
Endonuclease III, targets mitochondrial DNA—cardiomyocyte
|Alexopoulos et al., 2017 (61)||In vivo rabbit||Exenatide at reperfusion|
Cyclosporine-A at reperfusion parstatin 1-26 at reperfusion
|Additive effects with exenatide combined with either cyclosporine-A or parstatin 1-26 on reducing MI size||Exenatide-GLP-1 signaling—cardiomyocytes|
|Audia et al., 2018 (41)||In vivo rat||VX-765 and ticagrelor or cangrelor at reperfusion||Additive reduction in MI size after 2-h and 3-day reperfusion.||P2Y12 inhibitor—platelets|
VX-765, caspase 1 inhibitor—inhibition of cardiomyocyte pyroptosis
MPTP = mitochondrial permeability transition pore; VAD = val-ala-asp; Z-VAD = Z-val-ala-asp. Other abbreviations as in Table 1.
↵∗ Other criteria are as per Table 1.